Fulton Breakefield Broenniman’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.09M | Buy |
9,040
+1,530
| +20% | +$177K | 0.07% | 90 |
|
|
2025
Q4 | $791K | Buy |
7,510
+348
| +5% | +$32.7K | 0.05% | 106 |
|
|
2025
Q3 | $601K | Sell |
7,162
-786
| -10% | -$64.7K | 0.04% | 114 |
|
|
2025
Q2 | $629K | Buy |
7,948
+236
| +3% | +$18.8K | 0.04% | 111 |
|
|
2025
Q1 | $692K | Sell |
7,712
-488
| -6% | -$45.6K | 0.05% | 96 |
|
|
2024
Q4 | $816K | Sell |
8,200
-228
| -3% | -$23.5K | 0.06% | 95 |
|
|
2024
Q3 | $957K | Sell |
8,428
-519
| -6% | -$61.7K | 0.07% | 91 |
|
|
2024
Q2 | $1.11M | Buy |
8,947
+635
| +8% | +$81.8K | 0.08% | 86 |
|
|
2024
Q1 | $1.1M | Sell |
8,312
-107
| -1% | -$13.2K | 0.08% | 85 |
|
|
2023
Q4 | $918K | Sell |
8,419
-1,127
| -12% | -$117K | 0.07% | 91 |
|
|
2023
Q3 | $983K | Sell |
9,546
-99
| -1% | -$10.7K | 0.09% | 87 |
|
|
2023
Q2 | $1.11M | Sell |
9,645
-1,528
| -14% | -$173K | 0.09% | 86 |
|
|
2023
Q1 | $1.19M | Sell |
11,173
-481
| -4% | -$51.9K | 0.1% | 84 |
|
|
2022
Q4 | $1.29M | Buy |
11,654
+41
| +0.4% | +$4.19K | 0.11% | 82 |
|
|
2022
Q3 | $1M | Buy |
11,613
+8
| +0.1% | +$714 | 0.09% | 89 |
|
|
2022
Q2 | $1.06M | Sell |
11,605
-93
| -0.8% | -$8.24K | 0.09% | 94 |
|
|
2022
Q1 | $960K | Buy |
11,698
+1,569
| +15% | +$124K | 0.08% | 86 |
|
|
2021
Q4 | $776K | Buy |
10,129
+57
| +0.6% | +$4.54K | 0.06% | 105 |
|
|
2021
Q3 | $757K | Sell |
10,072
-600
| -6% | -$45.6K | 0.06% | 91 |
|
|
2021
Q2 | $830K | Sell |
10,672
-538
| -5% | -$40K | 0.07% | 89 |
|
|
2021
Q1 | $825K | Buy |
11,210
+4,941
| +79% | +$364K | 0.08% | 85 |
|
|
2020
Q4 | $489K | Sell |
6,269
-5,822
| -48% | -$445K | 0.06% | 94 |
|
|
2020
Q3 | $957K | Sell |
12,091
-53
| -0.4% | -$4.15K | 0.11% | 73 |
|
|
2020
Q2 | $896K | Buy |
12,144
+78
| +0.6% | +$5.87K | 0.11% | 77 |
|
|
2020
Q1 | $886K | Sell |
12,066
-1,245
| -9% | -$97.8K | 0.13% | 71 |
|
|
2019
Q4 | $1.16M | Buy |
13,311
+1,640
| +14% | +$135K | 0.13% | 82 |
|
|
2019
Q3 | $937K | Buy |
+11,671
| New | +$935K | 0.12% | 84 |
|
|
2015
Q2 | – | Sell |
-10,981
| Closed | -$602K | – | 126 |
|
|
2015
Q1 | $602K | Buy |
10,981
+331
| +3% | +$18.7K | 0.13% | 111 |
|
|
2014
Q4 | $577K | Buy |
+10,650
| New | +$593K | 0.13% | 116 |
|
|
2014
Q2 | – | Sell |
-11,650
| Closed | -$631K | – | 131 |
|
|
2014
Q1 | $631K | Buy |
11,650
+69
| +0.6% | +$3.57K | 0.16% | 115 |
|
|
2013
Q4 | $553K | Sell |
11,581
-9,052
| -44% | -$414K | 0.15% | 121 |
|
|
2013
Q3 | $937K | Buy |
+20,633
| New | +$942K | 0.25% | 103 |
|
Other funds holding MRK
VCM
VPM
Fulton Breakefield Broenniman's MRK Position: Q1 2026 in Review
Fulton Breakefield Broenniman increased its Merck (MRK) stake by 20% in Q1 2026, buying an estimated $177K and bringing the position to 9,040 shares worth $1.09M. The position accounts for 0.07% of the portfolio, ranked #90.
Fulton Breakefield Broenniman first reported a position in MRK in Q3 2013 and has held it in 32 quarters since. The position peaked at $1.29M in Q4 2022. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Fulton Breakefield Broenniman held 9,040 shares of Merck worth $1.09M as of Q1 2026.
- Fulton Breakefield Broenniman bought 1,530 Merck shares in Q1 2026, an estimated $177K.
- Merck made up 0.07% of Fulton Breakefield Broenniman's portfolio in Q1 2026, its #90 holding.
- Fulton Breakefield Broenniman first reported a position in Merck in Q3 2013 and has held it in 32 quarters since.
- Fulton Breakefield Broenniman's Merck position peaked at $1.29M in Q4 2022.
- 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Fulton Breakefield Broenniman's 13F filing for Q1 2026, filed 27 Apr 2026.